medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Title

2 Constructing a Finer-Grained Representation of Clinical Trial Results from ClinicalTrials.gov

3

4 Authors

5 Xuanyu Shi^{1,2}, Jian Du^{1,2}

- 6
- 7 Affiliations
- 8 1. Institute of Medical Technology, Peking University, Beijing, 100191, China
- 9 2. National Institute of Health Data Science, Peking University, Beijing, 100191, China
- 10

11 corresponding author: Jian Du (dujian@bjmu.edu.cn)

12

13 Abstract

14 Randomized controlled trials are essential for evaluating clinical interventions. 15 ClinicalTrials.gov serves as a primary repository for such data, yet extracting and synthesizing 16 information from it remains challenging. This study introduces a novel methodology for 17 constructing a detailed arm-centered representation of clinical trial results, moving beyond 18 the traditional PICO (Patient, Intervention, Comparison, Outcome) framework. The 19 representation attentively uncovers both efficacy outcomes and adverse drug events in safety 20 outcomes, promoting a dual-faceted understanding of intervention effects. Through a 21 structured acquisition, extraction, and initialization process, we present a knowledge graph 22 incorporating arm-level efficacy with safety results, categorizing outcomes into three distinct 23 groups: biomarkers, patient-reported outcomes, and clinical endpoints. The goal is to bridge 24 the gap between the generally described searchable design information and the specifically 25 detailed reported results. This approach aims to offer a structured dataset towards better 26 utilization and interpretation of ClinicalTrials.gov data, facilitating a more feasible and 27 complete evidence synthesis practice to include both positive and negative results hidden in 28 clinical trials registries.

- 29
- 30

31 Background & Summary

Clinical trial, specifically randomized controlled trial (RCT), is a method of perspective, random 32 33 allocated double-blinded clinical study. The goal of carrying out a clinical trial is to evaluate 34 the efficacy and safety or a single or multiple clinical interventions. It is also a requisite step 35 before a drug is approved for market release and sale. In the new evidence-based medicine 36 pyramid, randomized controlled trials are rated as the highest position, representing the most 37 reliable medical evidence¹. In today's medical research landscape, the accuracy and 38 accessibility of clinical trial data are paramount to ensuring research quality and advancing 39 scientific progress. ClinicalTrials.gov (CT.gov) serves as a pivotal repository for such data, hosting valuable information concerning numerous clinical trials. However, extracting and 40 41 synthesizing this information for further analysis remains a challenging endeavour.

42

The unique value inherent in CT.gov data has been demonstrated through various comparisons and analyses. When compared with results from PubMed, it has been noted that CT.gov often contains a more comprehensive report of adverse events². In CT.gov, safety results were reported at a similar rate as in peer-reviewed literatures, with more thorough reports of certain safety events³.

48

Discrepancies between different reports further underscore the necessity for a more
 systematic method of information retrieval from CT.gov. Selective reporting, as discussed in
 Note: MAS prejultistrates at the assessing has not been cutilizing per solver and antical after grid encoder solution.
 Although calls for leveraging CT.gov have been made, including in papers published by BMJ⁵,

53 the absence of automated tools for such a task is conspicuous. Despite its seemingly structured 54 facade, CT.gov presents substantial usability challenges which hinder the extraction of 55 published results.

56

57 Treating CT.gov research findings as a dataset embodies the principle of "process once, use 58 many times," transforming these findings into a computable body of knowledge. This 59 approach stands to significantly aid evidence synthesis. Despite a study from Johns Hopkins 60 University suggesting that CT.gov has not altered the conclusions of systematic reviews⁶, we 61 argue that the limited sample size in their analysis may have influenced these findings. Results 62 of randomized controlled trials (clinical trials, or RCT), are either published in scientific articles, 63 or reported on registry platforms, such as ClinicalTrials.gov (CT.gov), International Clinical 64 Trials Registry Platform (ICTRP), and Chinese Clinical Trial Registry, ChiCTR). Researchers found 65 that in the 91 trials with reported results on ClinicalTrials.gov and published in high-impact 66 journals, only 52% primary efficacy end points were described in both sources and reported 67 concordant results⁷. One of the possible and biggest explanation for this phenomenon is 68 selective publication or publication bias of clinical trials, which means there exists a higher 69 reporting rate of positive results in published literature compared to that in registries⁸.

70

71 This study intends to construct a finer-grained representation for arm-centered clinical trial 72 results by integrating efficacy and safety information. Our methodology enables: 1) a detailed 73 representation of "intervention" entities, transcending the traditional PICO (Patient, 74 Intervention, Comparison, Outcome) concept representation; 2) a systematic unveiling of 75 positive and negative results in efficacy outcomes; 3) a systematic disclosure of adverse drug 76 events (ADE) in safety outcomes; 4) a dual-faceted understanding of intervention effects from 77 both efficacy and safety perspectives. 5) By providing a structured, ready-to-use dataset, we 78 aspire to offer a new data source for meta-analysis, thereby facilitating a more discoverable 79 dataset to enhance evidence-based health decision-making.

80

86

81 The discrepancy between PICO information in the design phase and reported results 82 underscores the necessity for real meta-analysis which mandates results-oriented 83 information. Our study seeks to bridge this gap, fostering a more thorough and reliable 84 synthesis of evidence that can potentially elevate the standards of medical research and 85 practice.

87 **Existing studies.** There have been studies focusing on the structuring trial results data. 88 MedicineMaps ⁹ introduced a schema that represents clinical trial results from literature. The 89 schema lost information about the comparators, and was annotated manually. EvidenceMap¹⁰ 90 extracted PICO with observation data and efficacy relationships from 80 COVID-19 clinical trial 91 abstracts. Similarly, entities such as 'two groups' were also labeled as interventional, losing the ability to build comparable relationships. TrialStreamer¹¹ and TrialSummarizer¹² are tools 92 93 that extracts results from clinical trials in a large scale. For data from registry platform, CTKG¹³ 94 is a large knowledge graph version with embedding analysis of studies in the ClinicalTrials.gov 95 database. The knowledge graph follows the basic structure of ClinicalTrials.gov, with nodes 96 being sections and edges being 'has'. In 'outcome_analysis', same as the representation in 97 ClinicalTrials.gov, the compared arm groups were not separated as intervention versus 98 comparator as well.

99

100 In this study, we introduce an arm-level representation for efficacy and safety results in 101 studies registered on ClinicalTrials.gov. We optimize the data structure of clinical trials and 102 present study results with one-to-one comparable relationships. Each efficacy result is 103 represented by a relationship from an intervention arm group to the outcome, with the 104 efficacy as the relationship value, the comparator arm as an attribute. Each safety result is

105 represented by a relationship from an arm group to an adverse event, with the number of 106 affected subjects as an attribute.

107

108 To represent arm-level efficacy and safety results in a knowledge graph, we started with 109 acquiring registered clinical trials from register platform clinicaltrials.gov, followed by extraction of statistical significance and adverse events from reported results. After 110 standardizing arm groups and outcomes, we eventually constructed a knowledge graph 111 112 including results nodes, relationships and related attributes. Fig. 1 shows the overall workflow 113 of this study.



114 115 Figure 1. The overall workflow from data acquisition, results processing, to the final knowledge graph construction

Methods 116

117 **Data source**. On December 25th in 2022, We downloaded full registered clinical trials dataset directly from clinicaltrials.gov (https://classic.clinicaltrials.gov/AllPublicXML.zip). The dataset 118 119 is a compressed zip file containing all the individual XML file of each study named by the NCT 120 id. The total number of XML files of clinical trials downloaded is 437,173. We parsed and 121 transformed each file into a Pandas DataFrame with targeted information. From the reported 122 results section, we focus on efficacy and safety related to the intervention arm group, which 123 are stored under the statistical analysis and adverse events section.

124

125 Arm-level result.

126 In the context of clinical trials, an "arm" refers to a group of subjects receiving a particular 127 intervention, treatment, or control. The term is often used in randomized controlled trials (RCTs), which are considered the gold standard for evaluating the efficacy of different 128 129 treatments. In a typical RCT, participants are randomly assigned to different arms of the study

130 to minimize the influence of confounding variables and to allow for a fair comparison of the 131 interventions being tested.

132

133 Efficacy. In evidence based medicine, a piece of clinical trial results has to be described as 134 PICO(Population, Intervention, Comparator, Outcome) framework, along with the efficacy(E). 135 In clinical trials, population describes the characteristics of the selection of study subjects, such 136 as age, gender, condition; Intervention represent the treatment or strategy being studied, 137 which can be a drug, a lifestyle or a dietary plan. Comparator represents the strategy for 138 comparison with the intervention, which can a placebo method or a standard care. Outcome 139 describes what is being measure in the study to assess the efficacy and safety of the 140 intervention, which can be symptom relief, biomedical markers, or mortality rate.

141

142 The PICO framework is essential for formulating research questions and reviewing literatures 143 for relevant clinical studies. The search for the efficacy of an intervention, it is essential to 144 determine the anticipated corresponding population, comparator, and outcome. In natural 145 language, a clinical trial result can be expressed as: 'There exists a significant difference 146 between the intervention (I) and the comparator (C) on the outcome (O) in the population (P).

147

148 In this study, to evaluate the efficacy of an intervention on an outcome, we searched for the 149 statistical analysis section under each outcome in the study results page. For example, in the 150 study NCT01050998, under the outcome measure of the primary outcome 'Percentage of 151 Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 152 [CRP]) Response at Day 85 by Region' exists a list of statistical analysis results. As we can see 153 from an example of results (Fig. 2), the analysis section provides information such as groups, 154 p_value, and confidence interval. With these information we are able to create a relationship 155 between an intervention arm group and the primary outcome.

156

162

157 To parse the XML files for efficacy results, we extracted results in the form of relationships between 'groups' under each outcome measure and corresponding 'outcome': group--158 159 outcome. Each group—outcome pair is saved in a row in a Pandas dataframe, along with other 160 columns including other important attributes such as NCT_ID, p-value, statistical method, and confidence interval. An example is shown in Table 1. 161

<pre><analysis list=""></analysis></pre>
 Sinure 2 An example of statistical analysis in XMI file
Figure 2. All example of statistical analysis III AIVIL file

165 Table 1. An example of transformed dataframe of efficacy results

NCT_ID	groups	outcome_title		
NCT01049373	['Lymphdiaral Basistropfen	Change in FFbH-R Between Screening and 2 Weeks	0.0757	
	(HDC)', 'Placebo Solution']			
NCT03400800	['Inclisiran', 'Placebo']	Percentage Change in LDL-C From Baseline to Day 510	<0.0001	
NCT02912650	['Placebo', 'Ibuprofen 250 mg']	Pain Intensity Difference on 11-Point Numerical Scale (PID11)	<0.001	

NCT02954354	['Baloxavir', 'Oseltamivir']	Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir	0.5908			
NCT01795547	['Aripiprazole', 'Paliperidone']	Change From Baseline to Week 28 in the 'Interpersonal Relations' QLS Domain Score	0.07			
Statistical sia	nificance . To better and c	lirectly represent the efficacy of an intervention group				
on an outcom	e we created an automat	ic rule-based nineline to summarize analysis attributes				
for statistical	significance and eventual	ly presented as positive vs negative				
(1) check	if the result has valid n-v					
(1) thete (2) if no r	n the result has value p-value found shock if the	are sult has valid confidence interval				
(2) if 10μ	sults with a value, we lab	al the results as positive if it has a pivalue smaller than				
(5) 101 102	suits with p-value, we lab	er the results as positive in it has a p-value smaller than				
(4) for re	an to 0.05, and negative to	Julei wise				
(4) IOI IE	suits without p-value bi	turne neremeter (Odde Detie, Hererd Detie, etc.) er e				
statist	lical parameter is a ratio-	-type parameter (Odds Ratio, Hazard Ratio, etc.) or a				
	ance-type parameter (ivie	an Difference, Risk Difference ,etc.)				
(5) for re	suits with a ratio-type s	tatistical parameter, check if the number one (1) is				
conta	ined between the lower	and upper confidence interval limits. If one is not				
conta	ined, label the result as po	ositive, and negative otherwise				
(6) for re	sults with a difference-typ	be statistical parameter, check if the number zero (0) is				
conta	ined between the lower	and upper confidence interval limits. If zero is not				
conta	ined, label the result as po	ositive, and negative otherwise				
The detailed v	visualized pipeline and co	rresponding number of results in each step are shown				
in the result s	ection (Fig. 4).					
In the XML c	inical trial files downloa	ded from the website, arm groups are labeled with				
'Experimental	Experimental' and 'Comparator' in the study design section. But in the statistical analysis					
section, the ir	tervention arm group is	not distinguished from the comparator arm group by				
using a label.	The titles of the groups a	are also not always consistent with the titles from the				
study design	section, meaning it is no	t feasible to simply match the labels using the exact				
strings. Thus,	in this part, we utilized a t	transformer model BioBERT ¹⁴ ('dmis-lab/biobert-v1.1')				
to automatica	ally separate interventio	n arm group from comparator arm group. BERT,				
Bidirectional	Encoder Representations	s from Transformers, is a transformers-based deep				
learning mod	el that was introduced	by Google in 2018 ¹⁵ . It is a language model that is				
pretrained on	a large corpus of texts in	cluding Wikipedia. The model allows people to invoke				
weights (emb	eddings) of texts from t	he pretrained model without training on their own.				
BioBERT is a d	omain-specific adaptation	n of the original BERT and pretrained on a large corpus				
on biomedical	texts. With BioBERT, we	are able to perform various tasks such as named entity				
recognition ar	nd relation extraction on l	biomedical problems. In our specific task, we used the				
version BioBE	RT-Base v1.1 that is train	ed on around one million biomedical publications on				
PubMed.						
In this experim	nent, to prepare the data	in the form of the knowledge graph schema, we only				
kept results w	ith exact two arm groups	for comparison between intervention and comparator.				
Studies witho	ut valid labels of 'experir	mental' and 'comparator' arm groups from the study				
design section	were excluded.	, <u> </u>				
0						
We first produ	uced semantic embeddin	gs of the arm group titles from both the study design				
and statistical	analysis sections using Bi	oBERT. Then we calculated the similarities of semantic				
embeddings h	etween the arm groups f	rom different sections. Eventually we labeled the arm				
group from th	e statistical analysis sect	ion based on the label of the arm group that bas the				
o oup nom ti	p from the statistical analysis section based on the label of the arm group that has the					

highest similarity score from the study design section. For examples shown in Table 2, the

'Groups' column are the original stored groups information from ClinicalTrials.gov. After

212

- 214 comparing to columns 'Intervention' and 'Comparator', new columns 'Intervention group'
- 215 and 'Comparator' group' were created to represent the experimental and comparator groups.
- 216

217 Table 2 Example results of separation of arm groups into intervention vs. comparator in efficacy results

NCT_ID	Groups	Intervention	Comparator	Intervention_group	Comparator_group
NCT03064438	[ACU-D1 Ointment, ACU-	[ACCU-D1]	[Vehicle]	ACU-D1 Ointment	ACU-D1 Ointment
	D1 Ointment Vehicle]				Vehicle
NCT02553317 [Caplacizumab, Placebo]		[Caplacizumab]	[Placebo]	Caplacizumab	Placebo
NCT00650806 [Placebo, Canagliflozin		[Canagliflozin	[Placebo]	Canagliflozin 50 mg	Placebo
	50 mg]	(JNJ-28431754)]			
NCT02152605	[Placebo,UMEC/VI	[UMEC/VI]	[Placebo]	UMEC/VI 62.5/25 mcg	Placebo
	62.5/25 mcg]				
NCT00402246	00402246 [Remote Arm, In-Office		[In-Office	Remote Arm	In-Office Arm
	Arm]	Management]	Care]		

218

219 Safety. We integrated reported adverse events from clinicaltrials.gov to represent potential 220 safety harms related to the interventions. In the trial XML file, an adverse event is stored under 221 the <event> section, along with <sub title> and <count>, recording information including the 222 corresponding group, the number of affected subjects, and the number of subjects at risk. The 223 vast majority of adverse event titles are standardized into the Medical Dictionary for 224 Regulatory Activities (MedDRA¹⁶) by ClinicalTrials.gov. The parent elements that incorporate 225 the specific events cover health categories such as 'Cardiac disorders', 'Ear and labyrinth 226 disorders', etc. The events are also classified as serious events vs. other events, giving users 227 the ability to choose by event severity. In this study, we focus on serious adverse events of 228 which the number of affected subjects is none-zero.

229

230 In order to intuitively compare the efficacy and safety, we only kept serious adverse events in 231 the studies that have valid efficacy analysis results (54.8%, 6,429 out of 11,729). On 232 clinicaltrials.gov, not all the expressions of arm groups in adverse events sections are 100% 233 same as the ones in efficacy. In order to integrate efficacy and AE, we first tried using string 234 matching among the arm groups. For arm groups in AE that were not string-matched to an 235 arm group in efficacy, we utilized BioBert again to calculate the semantic similarities and 236 return the closest match. For each adverse event title, we calculated the semantic similarities 237 between the title and all the arm groups in the efficacy section. The closest matched arm group 238 was saved as a unique column in the dataframe, and we used the matched arm group for 239 integrating efficacy and safety. The columns for adverse events we saved in the dataframe 240 include 'NCT_ID', 'arm_title', 'event_title', 'category', 'serious/other', 'affected', 'at_risk', and 241 'matched group'. Each row can be comprehended as a reported adverse event named 242 'event_title' related to the arm group named 'matched_group' along with the number of 243 affected and at-risk participants (Table 3).

244

245 Table 3. Example adverse events with matched group in efficacy analysis section

NCT_ID	arm_title	event_title	category	serious/other	affected	at_risk	matched_group
NCT00977080	Oral Paricalcitol in the Oral Stratum	Abdominal pain	Gastrointestinal disorders	serious	1	72	Oral Paricalcitol in the Oral Stratum
NCT02254278	IMRT 5 Weeks	Syncope	Nervous system disorders	serious	1	147	IMRT 5 Weeks
NCT00509145	Laquinimod 0.6 mg	Uterine prolapse	Reproductive system and breast disorders	serious	1	550	Laquinimod
NCT00810199	Tocilizumab + Placebo	Clostridium difficile colitis	Infections and infestations	serious	1	276	Tocilizumab + Placebo
NCT02853331	Sunitinib	Hepatocellular injury	Hepatobiliary disorders	serious	1	425	Sunitinib

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- **Events co-occurrence.** In extra, we calculated co-occurrence weights among reported adverse events to provide the which AE is frequently occurred with another AE. We determined the co-occurrence of categories of SAEs by the following considerations: if both two categories have reported 'affected' participants in a same trial, and multiplying the 'affected/at_risk ratio' from the categories. $(\sum_{(a,b)\in S, a\neq b} c(a,b) \times (r(a) \times r(b)))$ (c:co-occurrence, r:ratio). This ratio based co-
- 252 $(\underline{\Sigma}_{(a,b)\in S, a\neq b}, \underline{C}_{(a,b)}) \times (r(a) \times r(b)))$ (c.co-occurrence, riveron, representing the
- 253 probabilistic extent of events co-occurrence.

254 255 **Outcome**

265

256 **MeSH extraction.** In clinical trial, expressions of outcomes vary across different studies. Thus 257 we processed all the unique outcomes using the MeSH(Medical Subject Headings) extraction 258 tool: NLM Medical Text Indexer(MTI). MTI allows us to extract MeSH terms from natural 259 languages, in our case, outcomes. MeSH represent the simplest representation of biomedical 260 languages for tasks including document retrieval, text classification, etc. For all the MeSH 261 terms extracted, we also recorded the parent terms along with the codings based on the tree 262 structure of MeSH. With MeSH terms of outcomes, we are able to not only standardize 263 outcome titles with different expressions, but also classify outcomes into different clinical 264 categories.

266 Outcome category. In clinical trials, the selection of outcomes has critical impact on the efficacy of the intervention. A study proposed categories of outcomes as Mortality/survival, 267 268 Physiological/clinical, Life impact, Resource use, and adverse events ¹⁷. By assumption, with 269 the same intervention, choosing biomarkers as the outcome potentially tend to produce 270 positive results ¹⁸. Also, biomarkers are usually used as surrogate endpoints that are easier to 271 measure. In contrast, in most cases clinical endpoints are more complicate to measure, and 272 tend to produce negative results. In this study, we classified the outcome titles into three 273 categories: Biomarker, Patient-reported outcome (PRO), and clinical endpoint.

- 274 Biomarker. We took the advantage of MeSH to identity biomarker outcomes. We first • 275 manually went through the MeSH tree to discover possible biomarker-related terms. 276 We found that the majority of the terms we discovered (such as 'E01.370.376.537.250-Brain Cortical Thickness', 'D12.776-Proteins', and 'D10.251-277 Fatty Acids') belong to the root category D(Chemicals and Drugs) and E(Analytical, 278 279 Diagnostic and Therapeutic Techniques, and Equipments). Thus, we preliminarily 280 selected the root categories D and E as the biomarker identifier in outcomes. If any of 281 the MeSH terms extracted from an outcome title starts with D or E, we labeled the outcome as biomarker. We excluded 'E05.318.308.980-Surveys and Questionnaires' 282 as it is a PRO related MeSH term. 40,525 results with unique 14,217 biomarker 283 outcomes were identified. 284
- 285 PRO. Patient-reported outcomes(PROs) are used to report the status of a patient's • health condition from the patient's persepective¹⁹. Research identified PROs and 286 inspected the inclusion of PROs in registered clinical trials from 2007 to 2013 and 287 found 27% of the trials used one or more PRO measures²⁰. Recently, the usage of PROs 288 289 in novel artificial intelligence(AI) clinical trials was assessed by researchers (152/627 290 trials)¹⁹. Both previously-mentioned studies used PRO databases such as PROQOLID 291 and GEM to match PROs in registered clinical trials. One of the major limits of exact 292 text-matching for outcomes in registered clinical trials is that the writings or 293 expressions are natural languages, meaning they can be inconsistent. In this study, we 294 simplified the searching words and took advantage of the extracted MeSH terms. To 295 identify PRO outcomes, we applied keyword matching on columns 'outcome_title' and 296 'outcome_mesh'. The keywords are 'Survey', 'Questionnaire', 'Patient Reported',

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

297 'Patient-Reported', 'Scale', and 'Score'. We labeled the outcome as PRO if any 298 lowercase of the keywords was matched in the outcome string. We eventually found 299 33,547 results with 9,820 unique PRO outcomes.

- 300 Clinical endpoint. In this study, we defined the disease-related outcomes as the • clinical endpoint outcomes. The root category C from MeSH tree represents 301 302 'Diseases'. We also added F03 (Mental Disorders) as a target disease-related category. 303 If any of the MeSH terms extracted from an outcome title starts with 'C' and 'F03', we 304 labeled the outcome as clinical endpoint. 23,557 results with 7,837 unique clinical 305 endpoint outcomes were identified.
- 306

307 In short summary, 25,758 (61.03%) unique outcomes were successfully identified as 308 biomarker, PRO, or clinical endpoint, contained in 76,575 (63.83%) efficacy results. We noticed 309 that there existed differences of the coverage of outcome categories between primary 310 outcomes and secondary outcomes. Table 4 shows the detailed coverage numbers of 311 biomarkers, PROs, and clinical endpoint outcomes.

312

313

Table 4. Coverage statistics of Identified categories in Primary and Secondary outcomes ('result' means numbers in 314 efficacy results, 'outcome' means numbers of unique outcomes in efficacy results)

	Primary (result)	Secondary (result)	Primary (outcome)	Secondary (outcome)
Total	23,252	92,966	10,624	30,408
Biomarker	9,321 (40.09%)	29,931 (32.20%)	4,105 (38.64%)	9,702 (31.91%)
PRO	4,378 (18.83%)	27,838 (29.94%)	2,072 (19.50%)	7,501 (24.67%)
Clinical	4,133 (17.77%)	18,700 (20.11%)	2,080 (19.58%)	5,537 (18.21%)
coverage	14,388 (61.88%)	59,738 (64.26%)	6,609 (62.21%)	18,429 (60.61%)

315

316 Knowledge graph construction.

317 A knowledge graph (KG) is a specialized graph-based data structure used for representing a 318 collection of knowledge, entities, and their relationships. In this study, we stored the clinical 319 trial entities (outcome, arm group, adverse event, etc.) and their relationships in a knowledge 320 graph for visual representation and complex data retrieval queries.

321

322 We created 3 main node types: intervention_arm, outcome, and adverse_event:

- 323 Intervention_arm. The intervention_arm node is interventional arm group from the • statistical analysis result section. The relationship representing the efficacy of results 324 325 is either 'positive' or 'negative', with intervention arm as starting node and outcome 326 as ending node, built based on the columns 'intervention group', 'outcome title', and 327 'siginificance' from each efficacy result row. 'Positive' relationships are shown in green 328 and 'negative' relationships are shown in red. Some intervention_arm nodes are 329 connected to a concept node that saves the mapped MeSH term of the 330 intervention_arm title.
- Outcome. The outcome node is clinical outcome used in each study. The outcome 331 • 332 node can be connected to an outcome_type node to exhibit the types of an outcome, 333 including biomarker, PRO, and clinical endpoint.
- 334 Adverse event. The adverse event node is reported serious adverse event in each • clinical trial. For adverse events, we built the relationship 'has ae' from the column 335 336 'intervention_arm' to 'event_title' from each adverse event result row. Each 337 adverse event node is connected to an adverse event category node, representing 338 the parent biomedical categories of the adverse event name.
- 339

340 We loaded the created nodes and relationships along with their attributes into the graph 341 database Neo4j (database version==5.3.0).

343 To summarize, we presented a pipeline to construct a knowledge graph to represent arm-level 344 clinical trial efficacy and safety results. Compared to existing large scale trial databases such 345 as AACT and CTKG, we curated a result database containing identified comparable arm groups in results section. We also integrated efficacy and safety results by connecting corresponding 346 347 arm groups, providing an evidence dataset for evaluating clinical interventions. We 348 constructed a knowledge graph based on the dataset, offering a data infrastructure for further 349 analysis and applications. However, current limitations include: (1) In efficacy results, multiple 350 testings are not adjusted yet. (2) Multiple arms were not included and classified as 351 interventional and comparator. (3) Current dataset only covers clinical trials with both efficacy 352 and safety results.

Data Records 354

353

355 Knowledge graph schema. The knowledge graph schema exhibits the most important nodes, 356 relationships, and attributes when evaluating clinical trial results. Compared to the sole 'has' 357 relationship in the CTKG, in order to better represent the RESULTS across different studies, we saved all the study-related information of the results in different relationships instead of 358 359 unique nodes, based on the efficacy and adverse event (Fig. 3). For efficacy, the schema shows 360 the significance, the comparator arm, the parameter value, NCT id, and condition. For safety, 361 the schema shows the affected/at risk ratio, NCT id, and severity. Also, for all the 3 main node 362 types, we applied different techniques described in the method section to give each node type 363 a standardized or taxonomic categories for data integrity and normalization. Table 5 shows 364 the counts of node types and relationships.



365 366

Figure 3. An overview of the schema of arm-level efficacy and safety knowledge graph

367 Table 5. Statistics nodes and efficacy and safety relationships. The relation count of efficacy is the number of results 368 with valid intervention group, comparator group and statistical significance. The relation count of safety is the 369 number of serious adverse events with valid arm group and event title.

No	de type 0	Count 0	Node type 1	Count 1	Relation name	Relation count
	Intervention_arm	10,364	Outcome	41,708	positive/negative	119,968
	Intervention_arm	10,364	Adverse_event	40,408	has_ae	803,052
	Intervention_arm	10,364	Concept	1439	ls_a	49,764
	Outcome	41,708	Outcome type	3	ls_a	76,575
	Adverse event	40,408	Adverse event category	28	ls_a	803,052

371 Efficacy. To determine the efficacy or statistical significance of an intervention on an outcome, 372 we used p-values and confidence intervals. However, these fields lacked clarity and uniformed 373 formatting. To transform the uncleaned string data into a computable format for our rule-374 based algorithm, we removed blanks in the strings, transformed the numbers to numeric, and 375 processed the mathematical operators in standard representations. After using the 376 classification pipeline, we introduced in the method section, we eventually distinguished 377 56.39% statistically negative results, and 43.61% statistically positive results.



positive: 43.61% negative: 56.39%

378 379

Figure 4. The pipeline and numbers of classification of positive vs. negative results

380 Safety. We investigated the number of affected subjects of SAEs related to the arm groups. In 381 this dataset, a total of 2,106,063 subjects (not necessarily unique individual subjects) were 382 affected by SAEs, and 3,538,554 were at risk. Table 6 shows the top 10 intervention mesh 383 terms of arm groups that are associated with the greatest number of affected subjects. Table 384 6 only included SAEs with valid one-to-one mesh terms and types. Note that this is not a causal 385 relationship between SAE and arm group. The reasons of appearances of SAEs can be related 386 to the subjects' personal health condition, trial design, disease complications, etc. Table 7 lists 387 the top SAE categories that are associated with the largest numbers of affected subjects.

388

389 Also note that this is only the safety results that from studies having efficacy results at the 390 same time, for the purpose of tracking original study for integrating efficacy and safety analysis. We imported the co-occurrence matrix to a network visualization software Gephi²¹ 391 392 and output the co-occurrence map of SAE categories (Fig. 5). In the co-occurrence map, each 393 node represents an adverse event category. Each edge represents the existence of co-394 occurrence between two categories. The width of edges represents the weighted co-395 occurrence scores. The size of nodes represents the sum of the scores. Table 8 lists the top co-396 occurrence edges between SAE categories, with corresponding calculated weights. The table 397 compares the degrees of co-occurrence of SAE categories. With the co-occurrence algorithm 398 (AR ratio), the SAE category 'Infections and infestations' has the highest degree of co-399 occurrence, meaning it is the most frequently and strongly accompanied by other SAEs.

400

401 Table 6. Numbers of affected subjects by different arm groups

Intervention_mesh	Intervention_type	Number of affected subjects
Darbepoetin alfa	Drug	16,968
Vorapaxar	Drug	14,575
Dapagliflozin	Drug	13,267
Denosumab	Drug	11,175
Darapladib	Drug	10,860
Epoetin Alfa	Drug	10,270

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

	1	
Vaccines	Biological	9,967
Ticagrelor	Drug	9,845
Evolocumab	Biological	9,317
Liraglutide	Drug	9,085

402 403

Table 7. Numbers of affected subjects by SAE categories

category name	Number of affected subjects
Infections and infestations	294,602
Cardiac disorders	286,035
General disorders	195,018
Gastrointestinal disorders	168,440
Respiratory, thoracic and mediastinal disorders	147,184
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	132,976
Nervous system disorders	129,127
Injury, poisoning and procedural complications	104,784
Vascular disorders	93,766
Blood and lymphatic system disorders	78,164

404



405 406

407408 Table 8. Top co-occurrence edges with ratio weights

SAE category name	SAE category name	Weight
Respiratory, thoracic and mediastinal disorders	Infections and infestations	7.386
General disorders	Infections and infestations	6.818
Cardiac disorders	Infections and infestations	6.003
General disorders	Blood and lymphatic system disorders	5.663
Blood and lymphatic system disorders	Infections and infestations	5.497

409

410 Knowledge graph: Antibiotic and infection. In order to present the functionality of evaluating efficacy and safety of an intervention based on the constructed knowledge graph, we were 411 412 consulted by Na He, a pharmacist from the Department of Pharmacy, Peking University Third Hospital. Na was interested in adverse events related to infections while antibiotic 413 414 'imipenem/cilastatin' being used to treat infections. We queried the knowledge graph, retrieved efficacy results by matching the 'intervention_group' and 'intervention_MeSH' with 415 416 'imipenem' or 'cilastatin', and retrieved adverse event results by matching the group and adverse events title 'event title' and parent category 'category' with the keyword 'infection'. 417 418

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

419 The trade-offs between efficacy and safety are crucial in clinical studies, especially the

420 population condition and potential adverse events belonging to the same clinical condition.

The queried relationships are shown in Fig. 6 and detailed SAE results are shown in Table 9. 421

422 The infection-related SAEs give us evidence which types of infections should be paid attention

423 when treated with imipenem/cilastatin.



- 424 425
- 426 427

Figure 6. An example KG that shows the case of infection-related adverse events while intervening with the antibiotic imipenem/cilastatin to treat infections. Orange nodes are SAEs, yellow nodes are interventional arm groups, purple nodes are outcomes, visualized in Neo4j Bloom

428 Table 9. Infection-related serious adverse events with antibiotic 'imipenem/cilastatin'

NCT_ID	arm_title	sub_title	category	affected	at_risk
NCT00515034	cIAI Treated With	urinary tract infection	Infections and	1	19
	Imipenem/Cilastatin		infestations		
NCT02321800	Imipenem/Cilastatin	Device related infection	Infections and	1	148
			infestations		
NCT00589693	Imipenem-cilastatin	Urinary tract infection	Infections and	1	112
			infestations		
NCT00589693	Imipenem-cilastatin	Device related infection	Infections and	1	112
			infestations		
NCT00589693	Imipenem-cilastatin	Fungal infection	Infections and	1	112
			infestations		
NCT00589693	Imipenem-cilastatin	Lung infection	Infections and	1	112
			infestations		
NCT00589693	Imipenem-cilastatin	Postoperative wound	Infections and	1	112
		infection	infestations		
NCT01506271	Relebactam 125 mg With	Clostridium difficile infection	Infections and	1	116
	Imipenem/Cilastatin		infestations		
NCT01506271	Relebactam 125 mg With	Postoperative wound	Infections and	1	116
	Imipenem/Cilastatin	infection	infestations		
NCT01721408	Imipenem/Cilastatin	Postoperative wound	Infections and	2	232
		infection	infestations		
NCT02452047	Group 1:	Lung infection	Infections and	1	31
	Imipenem+Cilastatin/Relebacta		infestations		
	m				
NCT02452047	Group 3: Open-Label	Escherichia urinary tract	Infections and	1	3
	Imipenem+Cilastatin/Relebacta	infection	infestations		
	m				

429

Technical Validation 430

431 We introduced the full pipeline from data collection, data processing to the final knowledge 432 graph in details. The knowledge graph and original dataset is transparent in the following

433 aspects: 1) The origin of data comes from ClinicalTrials.gov, which is an open-access platform 434 that everyone is able to download the full structured dataset. 2) The process of formation of 435 the knowledge graph is reproducible. The codes will be available to access publicly. 3) Users are able to adjust the knowledge graph based on provided codes and sub-datasets, providing 436 437 the flexibility to alter the data based on their own research interests. Next, we present three 438 case studies to validate the usability for exploratory analysis, consistency with external 439 resources, and **feasibility** for real scientific problems.

440

441 Case study 1: Positive vs. negative efficacy results across types of conditions, interventions, 442 and outcomes.

443 We investigated the ratio of positive and negative efficacy results across different dimensions 444 (Table 10). For technical validation, we also provide a biomarker outcome list for each 445 condition. Each list contains a list of biomarker-type outcomes with corresponding number of 446 positive/negative efficacy results. This dataset provides clinical researchers and practitioners 447 surrogate endpoints for measurement when it is infeasible, unethical, or ineffective to directly 448 evaluate clinical endpoints. This case confirmed the usability of the dataset and users are 449 capable of conduct exploratory data analysis from every dimension.

450

451 Table 10. Distribution of positive and negative efficacy results across different dimensions

	positive	negative	positive_rate	negative_rate
Outcome type				
Biomarker	14166	15148	48.33%	51.67%
Patient-reported outcome	12647	20900	37.70%	62.30%
Clinical endpoint	9820	13757	41.65%	58.35%
Intervention type				
Drug	43521	54294	44.49%	55.51%
Biological	5507	7168	43.45%	56.55%
Radiation	57	143	28.50%	71.50%
Behavioral	1019	2375	30.02%	69.98%
Genetic	18	53	25.35%	74.65%
Other	511	966	34.60%	65.40%
Device	1223	1919	38.92%	61.08%
Dietary Supplement	155	389	28.49%	71.51%
Procedure	147	380	27.89%	72.11%
Combination Product	71	48	59.66%	40.34%
Diagnostic Test	1	3	25.00%	75.00%
Health Problems				
Infections	2640	3660	41.90%	58.10%
Neoplasms	1152	1929	37.39%	62.61%
Musculoskeletal Diseases	4338	5108	45.92%	54.08%
Digestive System Diseases	1007	1352	42.69%	57.31%
Stomatognathic Diseases	544	660	45.18%	54.82%
Respiratory Tract Diseases	4520	6337	41.63%	58.37%
Otorhinolaryngologic Diseases	520	644	44.67%	55.33%
Nervous System Diseases	2090	5086	29.12%	70.88%
Eye Diseases	478	940	33.71%	66.29%
Urogenital Diseases	1438	1461	49.60%	50.40%
Female Urogenital Diseases and Pregnancy Complications	1614	1621	49.89%	50.11%
Cardiovascular Diseases	2071	2647	43.90%	56.10%
Hemic and Lymphatic Diseases	434	639	40.45%	59.55%
Congenital, Hereditary, and Neonatal Diseases and Abnormalities	1398	1325	51.34%	48.66%
Skin and Connective Tissue Diseases	3539	3870	47.77%	52.23%
Nutritional and Metabolic Diseases	6091	5331	53.33%	46.67%
Endocrine System Diseases	3546	3190	52.64%	47.36%
Immune System Diseases	4425	6122	41.96%	58.04%

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Pathological Conditions, Signs and Symptoms	5483	7817	41.23%	58.77%
Occupational Diseases	8	174	4.40%	95.60%
Chemically-Induced Disorders	107	150	41.63%	58.37%
Wounds and Injuries	131	331	28.35%	71.65%
Mental Disorders	2408	4575	34.48%	65.52%

452

Biomarker outcome set. We provide a dataset of biomarker outcomes with the most positive and negative efficacy results under each health problem. The dataset is provided in Supplementary Table 1. Note that the outcomes are not standardized by concept, meaning there might be variations of same outcomes that are not summed together. Besides, this example shows the top biomarker outcomes associated with health problems. In the full dataset, outcomes should be associated with the original condition name.

459

460 Case study 2: Top SAE categories comparison with FDA data

US Food and Drug Administration (FDA) manages an adverse event reporting database (FDA's
 Adverse Event Reporting System, FAERS) intending to support post-marketing safety
 surveillance for drug and biomedical products. Compared to RCT results on CT.gov, FAERS
 receive reports directly from healthcare professionals and consumers.

465

466 Simon Lafosse visualized the distribution of adverse events by body systems from FAERS²². The 467 visualization shows that systems such as 'General Disorders', 'Injury, Poisoning', and 'Skin' 468 have most of the reported AE cases from April 2018 to March 2019. Inspired of this work, with 469 results data of ClinicalTrials.gov in hand, we inspected the sum of numbers of affected subjects 470 under each SAE category between 2018 and 2019 (Fig. 7). In this case, we included all the 471 possible interventions (top 20 in Simon Lafosse's), and also visualized the distribution of SAE 472 by categories. 'Infections and infestations' and 'Cardiac disorders' are related to 38,929 and 473 38,000 reported affect subjects in this dataset. This case validates that our dataset can be used 474 to analyze SAE in clinical trials on a large scale. Also compared to the analysis of FDA data, we 475 found some common top condition categories such as 'Nervous system disorders', and 476 'Infections and infestations'. There is great potential of deeper analysis of SAE based on this 477 dataset since it has multiple levels of meta-data including co-occurrence weights, mapped 478 categories, corresponding efficacy results, etc. This case shows the consistency of ability to 479 analyze adverse events by condition category from ClinicalTrials.gov data, similar to other 480 analysis based on FDA data.





Figure 7. The distribution of health problems of serious adverse events by the number of affected subjects

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

484 Case study 3: Interventions with same condition and SAE category.

485 Multimorbidity and comorbidity are vital challenges to medical practice^{23,24}. We attempt to 486 find interventional arm groups found having associated SAE categories while used to treat the 487 same category. In this case, we selected 'Infections and Infestations' as the category since it is 488 the category that is associated most trial subject. Fig. 8 illustrates the KG retrieval of above 489 circumstance, with yellow nodes are intervention arm groups, orange nodes are SAEs, and 490 purple nodes are outcomes. This case validates that with real medical practice problem, this 491 knowledge graph has much potential to provide reliable, large-scale, and human-readable 492 evidence.



493 494

500

Figure 8. KG example in which both efficacy and safety outcomes are infections, visualized in Neo4j Bloom

495 We retrieved the arm groups and corresponding mesh terms and saved them to provide an 496 intervention set for researchers who want to find interventions that are tested positive for 497 efficacy and are observed with SAEs from the same condition category at the same time. This 498 knowledge graph can also be used to retrieve for other conditions. The full arm groups set and 499 corresponding mesh terms are in the following:

501 Arm groups set: ['Vaniprevir 24 Week Arm', 'Rabipur Group', '7vPnC After Infant Series Dose 502 3', 'MK-3415 + SOC', 'Nevirapine QD+BID', 'Vaccine', 'V710 60 μg', 'CD24Fc', 'Enhanced 503 Treatment', 'Priorix-Tetra Group', 'CCI Vaccine', 'Group D: TDV Lyophilized', 'Control', 504 'HIV+/Cervarix Group', 'rhNGF 20 μq/ml', 'Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week', 'V419', 'Placebo + INFANRIX Hexa', 'QIVc (≥4 to <18 Years)', 'Baricitinib + SOC', 'ADV-TDF', 505 506 'Ziprasidone', 'Reltecimod (AB103) 0.5 mg/kg', 'Cohort 1-Engerix-B/Prevnar-Hiberix Group', 507 'Arm 1: Metronidazole Plus Miconazole', 'Neutrolin Arm', 'SB213503 Lot 1 + M-M-R Group', 'Azithromycin', 'DTG + RPV', 'Twinrix Group', 'IVV Vaccine', 'QIVc (≥18 Years)', '7vPnC After the 508 509 Infant Series', 'ABC/ DTG/ 3TC', 'Immediate Introduction of Everolimus', 'Baloxavir Marboxil', 'PTX+ART', 'RotaTeq™', '4200mg Bamlanivimab', 'MMR Group', 'DTaP (Catch-up 7vPnC)', 'CAB 510 LA+RPV LA (Q4W)', 'Placebo - Asia', 'Immediate ART', 'Telaprevir 12 Week+Peg-IFN-alfa-511 512 2a,RBV 48 Week', 'Letermovir', 'Cyclosporine', 'Bimekizumab (PPS)', 'Maribavir 400 mg', 'V501', 513 'Investigational Device', 'Oral Care With Influenza and Pneumococcal Vaccines', 'MK-6072 +

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

514 SOC', 'Placebo for 24 Weeks', 'TMC435 150mg 12Wks PR24/48', 'Cohort 2', 'Td Adsorbed 515 Vaccine', 'Baloxavir', 'Pneumosil', 'CT-P59 40 mg/kg Group (Part 2)', 'Test', 'Delafloxacin', 'Zoster-022 GSK1437173A 70-79YOA Group', 'Group 1: QIV-HD', 'Phase 3: 700 mg 516 Bamlanivimab + 1400 mg Etesevimab', 'Cohort 3', 'Azithromycin + Chloroquine', 'Maribavir 100 517 518 mg BID', 'Camostat Mesilate', '7vPnC After 2-Dose Infant Series', 'V260 With Staggered or 519 Concomitant EPI', 'Anaferon for Children', 'M72AS01 Group', 'Double-Blind Period - Vicriviroc 520 20 mg Plus an ART Regimen', 'MEDI8897 50 mg', 'MK-8237', 'TIV (Elderly)', 'Peginterferon Alfa-521 2a + Ribavirin', 'Clinically Driven Monitoring (CDM)', 'Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 522 24 Week', 'Raltegravir 800 mg q.d.', 'V419 Lots A, B, and C Combined', 'MK-3415A + SOC', 523 'Combined Patients Receiving 74 Gy RT', 'SYN-004', 'Nevirapine', 'Cohort 3 (Placebo, 2-5 Yrs)', 524 'Camostat Mesylate', 'Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week', 525 'DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)', 'TDV Lot 3', 'qHPV Vaccine in Base Study', 526 'Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week', 'Double-Blind Period - Vicriviroc 30 mg Plus an ART Regimen', 'MVA-NP+M1 Group', 'Maternal Chloroquine Prophylaxis', 'FluLaval™ 527 528 Quadrivalent Group', '4 rhNGF10 Phase 2 treatment', 'V114', 'High-Dose Quadrivalent Influenza Vaccine (QIV-HD)', 'GSK1437173A Group', 'PR5I', 'Stopped Cotrimoxazole 529 530 Prophylaxis', 'GSK1437173A Overall Ages Group', 'AZD7442', 'Telaprevir 24 Week+Peg-IFN-531 alfa-2a 24 Week', 'Test Product', 'TOTAL 2-sites, TRC', 'Cohort 1', 'Arm A: hIVIG', 'Posaconazole 100 mg QD for 24 Weeks', 'Remdesivir', 'Menjugate Comparator [6-12W] Group', 'HIV-532 /Cervarix Group', 'Vaniprevir 12 Week Arm', 'Participants Who Received DTG/3TC FDC', '4-sites, 533 534 1-week WITH HRIG', 'Daclatasvir, 60 mg, 12-Week Cohort', 'Intervention', '13vPnC', 'Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI Maintenance', 'VeroRab Comparator [5-17M] Group', 535 536 'Group D', 'PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks', 'Cohort 3 eTIV (3-8 Years)', 'Sotrovimab (500 mg IV)', 'Filgotinib', 'rMenB All', 'Azelaic Acid Foam, 15% (BAY39-6251)', 'QIV-HD', 537 'Placebo', 'TIV (3-8 Years)', 'Phase 2: 2800 mg Bamlanivimab + 2800 mg Etesevimab', 'TDV Lot 538 539 2', '13vPnC After Toddler Dose', 'AZD1222', 'Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 540 Week', 'Agriflu', 'Period 2: Tacrolimus']

541

Mesh terms set: ['taurolidine', 'peginterferon alfa-2b', 'metronidazole', 'chloroquine', 542 543 'paclitaxel', 'acetaminophen', 'valganciclovir', 'lamivudine', 'efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination', 'terbinafine', 'loratadine', 'vincristine', 'adapalene', 544 545 'sulfadoxine', 'everolimus', 'antibodies', 'interferon alpha-2', 'ribavirin', 'trimethoprim, 546 sulfamethoxazole drug combination', 'rho(d) immune globulin', 'immunoglobulins', 547 'methylprednisolone hemisuccinate', 'thrombin', 'peginterferon alfa-2a', 'darunavir', 'mycophenolic acid', 'alemtuzumab', 'diphenhydramine', 'nevirapine', 'tenofovir', 'cyclosporine', 548 'infliximab', 'cetuximab', 'cyclosporins', 'sirolimus', 'cobicistat', 'promethazine', 'gamma-549 550 globulins', 'trimethoprim', 'mometasone furoate', 'tofacitinib', 'emtricitabine, tenofovir disoproxil fumarate drug combination', 'thymoglobulin', 'maribavir', 'carboplatin', 551 552 'bamlanivimab', 'basiliximab', 'pharmaceutical solutions', 'gelatin sponge, absorbable', 'heparin', 'atazanavir sulfate', 'azelaic acid', 'fanasil, pyrimethamine drug combination', 553 'calcium heparin', 'clindamycin', 'tazarotene', 'vaccines', 'posaconazole', 554 'interferons', 555 'olopatadine hydrochloride', 'heptavalent pneumococcal conjugate vaccine', 'ceftriaxone', 'ivermectin', 'simeprevir', 'rilpivirine', 'clotrimazole', 'clindamycin phosphate', 'ganciclovir', 556 557 'sulfamethoxazole', 'oseltamivir', 'abacavir', 'raltegravir potassium', 'miconazole', 'mitogens', 558 'adalimumab', 'amoxicillin', 'tacrolimus', 'nicotinic acids', 'antibodies, monoclonal', 'epinephrine', 'interferon-alpha', 'remdesivir', 'pyrimethamine', 'cobicistat mixture with 559 560 darunavir', 'camostat', 'ziprasidone', 'efavirenz', 'immunoglobulins, intravenous', 'artemether, lumefantrine drug combination', 'adefovir dipivoxil', 'gabexate', 'clindamycin palmitate', 561 562 'letermovir', 'methylprednisolone', 'ganciclovir triphosphate', 'emtricitabine tenofovir alafenamide', 'ophthalmic solutions', 'zidovudine', 'lamivudine, zidovudine drug combination', 563 564 'prednisone', 'emtricitabine', 'amodiaquine', 'benzoyl peroxide', 'azithromycin', 'etoposide', 'antilymphocyte serum', 'bleomycin', 'dideoxynucleosides'] 565

Code Availability 566

567 The source codes of data collection, processing and analysis are stored at: (https://github.com/xuanyshi/clinical-trials-finer-grained-representation). 568

Acknowledgements 570

571 This work is funded by the National Key R&D Program for Young Scientists (2022YFF0712000).

572

569

573 We thank Na He (pharmacist, Department of Pharmacy, Peking University Third Hospital) for 574 drug efficacy and adverse events scenarios. We also thank research interns Xiaofan Li (Beijing 575 Institute of Technology), Zitao Liang (Peking University), and Zhanyuan Jiang (Beijing University 576 of Posts and Telecommunications) for help with data processing and analysis.

577

578 Author contributions

- 579 Xuanyu Shi was responsible for major data collection, pre-processing and analysis, XS was also 580 responsible for manuscript writing.
- 581 Jian Du and Xuanyu Shi conceptualized the research. JD was also responsible for background 582 drafting and manuscript polishing.

Competing interests 584

- 585 We declare no conflict of interest.
- 586

583

References 587

- 588 Murad, M. H., Asi, N., Alsawas, M. & Alahdab, F. New evidence pyramid. BMJ Evidence-1 589 Based Medicine **21**, 125-127 (2016).
- 590 Dunn, A. G. & Bourgeois, F. T. Is it time for computable evidence synthesis? Journal of 2 591 the American Medical Informatics Association 27, 972-975 (2020).
- 592 3 Chen, K. Y., Borglund, E. M., Postema, E. C., Dunn, A. G. & Bourgeois, F. T. Reporting 593 of clinical trial safety results in ClinicalTrials. gov for FDA-approved drugs: A cross-594 sectional analysis. Clinical Trials 19, 442-451 (2022).
- 595 4 Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C. & Altman, D. G. Empirical 596 evidence for selective reporting of outcomes in randomized trials: comparison of 597 protocols to published articles. Jama 291, 2457-2465 (2004).
- 598 5 Jia, Y. et al. Effect of redundant clinical trials from mainland China evaluating statins 599 in patients with coronary artery disease: cross sectional study. bmj 372 (2021).
- Wilson, L. M., Sharma, R., Dy, S. M., Waldfogel, J. M. & Robinson, K. A. Searching 600 6 601 ClinicalTrials. gov did not change the conclusions of a systematic review. Journal of 602 Clinical Epidemiology 90, 127-135 (2017).
- 7 Becker, J. E., Krumholz, H. M., Ben-Josef, G. & Ross, J. S. Reporting of results in 603 604 ClinicalTrials. gov and high-impact journals. Jama 311, 1063-1065 (2014).
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A. & Rosenthal, R. Selective 605 8 606 publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358, 252-260 (2008). 607
- 608 9 Mainberger, F. et al. MedicineMaps: A tool for mapping and linking evidence from 609 experimental and clinical trial literature. (2013).
- Kang, T. et al. EvidenceMap: a three-level knowledge representation for medical 610 10 611 evidence computation and comprehension. Journal of the American Medical 612 Informatics Association 30, 1022-1031 (2023).
- 613 11 Marshall, I. J. et al. Trialstreamer: A living, automatically updated database of clinical 614 trial reports. Journal of the American Medical Informatics Association 27, 1903-1912 615 (2020).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297572; this version posted October 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Ramprasad, S., Marshall, I. J., McInerney, D. J. & Wallace, B. C. in Proceedings of the conference. Association for Computational Linguistics. Meeting. 236 (NIH Public Access).
- Chen, Z. et al. A knowledge graph of clinical trials (CTKG). Scientific reports 12, 4724 (2022).
- Lee, J. et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics 36, 1234-1240 (2020).
- Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. Bert: Pre-training of deep bidirectional transformers for language understanding. arXiv preprint arXiv:1810.04805 (2018).
- Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug safety 20, 109-117 (1999).
- Dodd, S. et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. Journal of clinical epidemiology 96, 84-92 (2018).
- Fleming, T. R. & Powers, J. H. Biomarkers and surrogate endpoints in clinical trials. Statistics in medicine **31**, 2973-2984 (2012).
- Pearce, F. J. et al. The role of patient-reported outcome measures in trials of artificial intelligence health technologies: a systematic evaluation of ClinicalTrials. gov records (1997–2022). The Lancet Digital Health 5, e160-e167 (2023).
- Vodicka, E. et al. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials. gov (2007–2013). Contemporary clinical trials 43, 1-9 (2015).
- Bastian, M., Heymann, S. & Jacomy, M. in Proceedings of the international AAAI conference on web and social media. 361-362.
- Lafosse, S. Watch your medicine drugs: the adverse events and medicinal drugs, <https://public.tableau.com/app/profile/simon.lafosse/viz/WYMD-Top20v0 5/WYMD> (2019).
- Kuan, V. et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. The Lancet Digital Health 5, e16-e27 (2023).
- Guthrie, B., Payne, K., Alderson, P., McMurdo, M. E. & Mercer, S. W. Adapting clinical guidelines to take account of multimorbidity. Bmj 345, e6341 (2012).

Supplementary Table 1. Positive and negative biomarker outcome set of each health problem

heal	health_problem_t	outcome_title	pos	outcome_title	neg
th_p	itle		itiv		ativ
em			um		um
_me					
sh C01	Infections	Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity	45	Percentage of Participant With Normal Alanine Aminotransferase	40
		(OPA) Following Vaccination With Separate V114 Lots		(ALT) Levels	
C01	Infections	Percentage of Participants Achieving the Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Threshold Value of >0.35 µg/mL for the	26	Percentage of Participants Who Were HBeAg Negative	33
		13 Common Serotypes in V114 and Prevnar 13™: 1 Month Post			
604	lafa di an	Vaccination 3	22		24
C01	Infections	Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M). Urine Albumin/Creatinine. Urine B2M/Urine	22	Change From Baseline in HBSAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100	31
		Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and			
C01	Infoctions	Urine RBP 4/Urine Creatinine at Weeks 24, 48	21	Sarahuna anacific Geometric Mann Concentration of IrG Antibody	21
01	mections	(GMTs) 1 Month After Vaccination for 12 Common Serotypes in	21	Service specific debinetite mean concentration of igo Antibody	21
		13vPnC/23vPS Group Relative to 23vPS Group and 23vPS/23vPS Group			10
C01	Infections	Comparison of Serotype-specific Geometric Mean Concentration of IgG Antibody Response 4 Weeks After a 3-dose Primary Series to 4 Weeks	20	Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100	19
		After a Booster Dose		(
C04	Neoplasms	Progression-Free Survival (PFS)	40	PFS in Subgroups That Were Defined by Germline PDGFRB	48
C04	Neoplasms	AUC(0-2h) of [6R]-5,10-methylene-THF	6	OS in Subgroups That Were Defined by Germline PDGFRB	46
				Polymorphisms	
C04	Neoplasms	AUC(0-2h) of [6S]-5-THF AUC(0-2h) of [6SB]-5-formyl-THE	6	PFS in Subgroups That Were Defined by RNA Expression Profile	35
04	пеоразніз		Ū	VEGFR2 Polymorphisms	24
C04	Neoplasms	AUC(Last) of [6R]-5,10-methylene-THF	6	PFS in Subgroups That Were Defined by Germline VEGFR2	22
C05	Musculoskeletal	Change From Baseline in Serum Uric Acid Levels at Day 1, Day 3, Day 7.	44	Polymorphisms Change From Baseline in Plasma Levels of Hypoxanthine at Day 1.	36
205	Diseases	Day 11, Day 14 and Follow-up		Day 7, Day 14, and at Follow-up	50
C05	Musculoskeletal	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks	27	Current Pain During the Hospital Stay Assessed by the Pain NRS	26
C05	Musculoskeletal	c, 4, 6, 12, 10, 20, 24, 52, 40, 46, and 52 Change From Baseline in C-reactive Protein (CRP) at Weeks 2, 4, 8, 12, 16.	24	Change From Baseline in Predictive Biomarkers: Amvloid A.	26
	Diseases	20, 24, 32, 40, 48, and 52		Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand	
COF	Musculoskolotal	Change From Paceline in Placma Levels of Yanthine at Day 1, Day 7, Day	22	13, Interleukin 6, Macrophage-Derived Chemokine	20
005	Diseases	14, and at Follow-up	22	Day 14, and at Follow-up	20
C05	Musculoskeletal	Percent Change From Baseline in Serum Urate Levels at Week 28.	13	Change From Baseline in C-Reactive Protein (CRP) at Weeks 1, 2, 4,	18
C06	Diseases	Change From Baseline in Quantitative Henatitis B Surface Antigen (Log	17	8, 12 and 16 Percentage of Participant With Normal Alapine Aminotransferase	40
000	Diseases	qHBsAg) Over Time	1/	(ALT) Levels	40
C06	Digestive System	Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV	14	Percentage of Participants Who Were HBeAg Negative	33
C06	Diseases Digestive System	DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100 Absolute Change in Percent Predicted Forced Expiratory Volume in 1	10	Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40.	31
	Diseases	Second (ppFEV1)		52, 64, 76, 88, and 100	
C06	Digestive System	Progression Free Survival (PFS)	6	Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid	19
C06	Digestive System	AUC(0-2h) of [6R]-5,10-methylene-THF	6	Progression Free Survival (PFS)	6
	Diseases			• • • •	
C07	Stomatognathic	AUCgly(0-90) for Test Zinc-IPMP, Test Zinc Non-IPMP, Positive Control, Non-SLS Negative Control and SLS Negative Control	6	Anti-S.Pneumoniae Antibody Concentration in US Sub-cohort of Pooled MMR Groups	12
C07	Stomatognathic	Enamel Fluoride Uptake	5	AUClive:Dead(0-90) for Test Zinc-IPMP, Test Zinc Non-IPMP, Positive	10
	Diseases			Control, Non-SLS Negative Control and SLS Negative Control	
C07	Stomatognathic Diseases	AUCregrowth(0-90) for Test Zinc-IPMP, Test Zinc Non-IPMP, Positive Control, Non-SLS Negative Control and SLS Negative Control	4	AUCregrowth(0-90) for Test Zinc-IPMP, Test Zinc Non-IPMP, Positive Control, Non-SLS Negative Control and SLS Negative Control	6
C07	Stomatognathic	Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel	3	AUCgly(0-90) for Test Zinc-IPMP, Test Zinc Non-IPMP, Positive	3
	Diseases	Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test		Control, Non-SLS Negative Control and SLS Negative Control	
		Rinse 3) Placebo Dentifrice+ Sterile Water Rinse			
C07	Stomatognathic	Adjusted Mean Percentage Surface Microhardness (SMH) Recovery of	3	Number of Participants With Unplanned Breaks in Cisplatin	2
	Diseases	Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1)Test Dentifrice+Sterile Water Rinse 2)Reference Dentifrice+Sterile Water Rinse		Chemotherapy Treatment	
		3)Placebo Dentifrice+ Sterile Water Rinse			
C08	Respiratory Tract	Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity	45	Change From Baseline in Specific Imaging Airway Volume (siVaw),	100
	Diseases	(OPA) Following vaccination with Separate V114 Lots		Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes	
				and 5 Regions at Screening, Day 12 and Day 28	
C08	Respiratory Tract	Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI	34	Change From Baseline in Imaging Airways Volume: iVaw, Measured at ERC and TLC Scan Conditions. Presented in Longitudinal and	100
	Discuses	The following the cessation of hepeat bose freatment with Hyvi		Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at	
				Screening, Day 12 and Day 28	
C08	Respiratory Tract Diseases	Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment	28	Change From Baseline in Imaging Airways Resistance (iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan	60
		(- ,		Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at	
C08	Rospiratory Tract	Comparison of Sorature specific Geometric Mean Concentration of IrG	20	Screening, Day 12 and Day 28 Change From Paceline in Imaging Specific Ainways Periotance:	60
008	Diseases	Antibody Response 4 Weeks After a 3-dose Primary Series to 4 Weeks	20	siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan	00
		After a Booster Dose		Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at	
C08	Respiratory Tract	Comparison of Serotype-specific Geometric Mean Concentration of IgG	20	Screening, Day 12 and Day 28 PFS in Subgroups That Were Defined by Germline PDGERB	48
	Diseases	Antibody Response 4 Weeks After a Booster Dose to One Year After a		Polymorphisms	
600	Oberhinslerensels	Booster Dose		Change Free Developing in AM and DM Developing interesting Flags Date	
C09	gic Diseases	Change From baseline in now-specific IgE Levels at week 8	4	(PEFR)	11
C09	Otorhinolaryngolo	Pain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and	3	Change From Baseline in Forced Expiratory Volume in One Second	3
C00	gic Diseases	3 Hours After the First Lozenge the Effect of Squeezable Bottle and Swings on Clinical Effectiveness in	2	(FEV1) Change From Baseline in Forced Vital Conacity (FVC)	2
C03	gic Diseases	Sinusitis Children	2	change from basenne in forced vital CapaCity (FVC)	3
C09	Otorhinolaryngolo	Percentage of Participants Who Discontinued Study Drug Due to an	2	Change From Baseline in Forced Expiratory Flow (FEF) Between	3
00	gic Diseases Otorhinolan/ngole	Adverse Event Total Nasal Airflow on Day 8 Measured Using Active Anterior	2	25% and 75% of the Vital Capacity (FEF25%-75%) Change From Baseline 24-hour Urinary Free Corticol Level	2
235	gic Diseases	Rhinomanometry (AAR)		the second descence by note officing the consolected	
C10	Nervous System	CSF IL-6, sTREM2, HMGB1, Albumin, IgG	10	Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C,	12
1	Diseases			Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine	
C10	Nervous System	ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging	6	Percentage of Participants Achieving hSBA Vaccine Seroresponse	10
1	Diseases	Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1)	1	tor Meningococcal Serogroups A, C, Y And W Following Vaccination	
C10	Nervous System	Mean Blood Flow Velocity in Middle Cerebral Artery	5	Incidence of Non-delirium Complications After Surgery	8
1	Diseases	· · · · ·	1		1

C10	Nervous System	Total Cumulative Prednisone Dose	4	Change From Baseline in Peak Work (in Watts/kg) During Exercise Testing at Week 12 in Part 1	7
C10	Nervous System Diseases	Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and	4	Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.	4
C11	Eye Diseases	Triglycerides Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year	8	Percentage of Ranibizumab Re-injections Received Over 28 and 52	10
C11	Eye Diseases	Ex Vivo Total Cholesterol Uptake at Day 30	8	Weeks Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48	7
C11	Eye Diseases	Mean Number of Macular Laser Treatments From Baseline Through Months 24 and 36	4	Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over	6
C11	Eye Diseases	Change From Baseline in Visual Acuity (VA): Double Masked Phase	4	Distribution of Change in Visual Acuity (Letters) From Baseline to 1	4
C11	Eye Diseases	Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as	4	Loss of Visual Acuity	3
C12	Urogenital	Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)	12	Systolic, Diastolic and Mean Blood Pressure at Week 0, 3, 6, 12, and 16	12
C12	Urogenital	Change From Baseline to Day 90 in Serum Potassium	7	Blastocyst Quality, Intention-to-treat (ITT) Analysis Set	7
C12	Urogenital	Change From Baseline in eGFR	7	Creatinine Clearance (CrCl) in the Immediate Post-transplant Period	6
C12	Urogenital Diseases	Progression-Free Survival (PFS)	5	Pharmacokinetics: AUC(0-∞) of Tadalafil	6
C12	Urogenital Diseases	Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)	4	Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides	5
C13	Female Urogenital Diseases and Pregnancy Complications	Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)	12	Systolic, Diastolic and Mean Blood Pressure at Week 0, 3, 6, 12, and 16	12
C13	Female Urogenital Diseases and Pregnancy Complications	Change From Baseline to Day 90 in Serum Potassium	7	Blastocyst Quality, Intention-to-treat (ITT) Analysis Set	7
C13	Female Urogenital Diseases and Pregnancy Complications	Change From Baseline in eGFR	7	Creatinine Clearance (CrCl) in the Immediate Post-transplant Period	6
C13	Female Urogenital Diseases and Pregnancy Complications	Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein to Creatinine Ratio (UPCR)	4	Progression Free Survival (PFS)	5
C13	Female Urogenital Diseases and Pregnancy Complications	Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein	4	Change From Baseline to Day 90 in eGFR	5
C14	Cardiovascular Diseases	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.	27	Inflammatory Mediator Levels, Interleukin-1b, Interleukin 6 and Tumor Necrosis Factor (TNF) (pg/ml)	14
C14	Cardiovascular Diseases	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.	24	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 4	12
C14	Cardiovascular Diseases	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.	23	Change From Baseline in Plasma Concentration of Serum N- terminal Pro-Brain Natriuretic Peptide (NT-proBNP) at Months 5, 9,	12
C14	Cardiovascular	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood	22	13, 17, 21, 25, 29, 35, 37, 42, 48 and Final Visit Change From Baseline in Urine Albumin-to-Creatinine Ratio at	12
C14	Cardiovascular Diseases	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.	22	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure	11
C15	Hemic and Lymphatic Diseases	Mean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period	10	Mean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period	7
C15	Hemic and Lymphatic Diseases	Change From Baseline in Hematocrit	8	Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period	6
C15	Hemic and Lymphatic Diseases	Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause	7	Change From Baseline in Reticulocyte Count	6
C15	Hemic and Lymphatic Diseases	Mean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period	7	Progression-free Survival (PFS)	5
C15	Hemic and Lymphatic Diseases	Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period	6	Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause	5
C16	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Change From Baseline in Serum Uric Acid Levels at Day 1, Day 3, Day 7, Day 11, Day 14 and Follow-up	44	Change From Baseline in Plasma Levels of Hypoxanthine at Day 1, Day 7, Day 14, and at Follow-up	36
C16	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Change From Baseline in Plasma Levels of Xanthine at Day 1, Day 7, Day 14, and at Follow-up	22	Change From Baseline in Plasma Levels of Xanthine at Day 1, Day 7, Day 14, and at Follow-up	20
C16	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Percent Change From Baseline in Serum Urate Levels at Week 28.	13	Fraction of Inspired Oxygen (FiO2) (Percent) During the First 24 h and up to Day 7	11
C16	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Percent Change From Baseline in Serum Urate Levels at Final Visit	13	Oxygen Requirement and Ventilatory Support SpO2/FiO2 Ratio	10
C16	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)	10	Change From Baseline in Peak Work (in Watts/kg) During Exercise Testing at Week 12 in Part 1	7
C17	Skin and Connective Tissue Diseases	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52	27	Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine	26
C17	Skin and Connective Tissue Diseases	Change From Baseline in C-reactive Protein (CRP) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52	24	Change From Baseline in C-Reactive Protein (CRP) at Weeks 1, 2, 4, 8, 12 and 16	18
C17	Skin and Connective Tissue Diseases	Change From Baseline in Percentage Body Surface Area at Week 2, 4, 8 and 12	8	Change From Baseline in Flow Cytometry: 6 Colour TB Natural Killer (NK) Panel- CD16+CD56+, CD19, CD3, CD3+CD4+	16
C17	Skin and Connective Tissue Diseases	Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Weeks 12, 16, 28, 40, and 52: Double-blind Period	8	Change From Baseline in Predictive Biomarkers: Chitinase 3 Like 1, Matrix Metalloproteinase 3 (MMP-3)	14
C17	Skin and Connective Tissue Diseases	Percentage of Participants Achieving Patient Global Assessment (PtGA) Response of 'Clear (0)' or 'Almost Clear (1)' and Greater Than or Equal to 2 Points Improvement From Baseline at Weeks 12, 16, 28, 40 and 52:	8	Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16-, CD14lo+CD16br+	14

C18	Nutritional and Metabolic Diseases	Change From Baseline in Serum Uric Acid Levels at Day 1, Day 3, Day 7, Day 11, Day 14 and Follow-up	44	7-Point Self-Monitored Blood Glucose (SMBG) Profiles	53
C18	Nutritional and Metabolic	Change From Baseline in Fasting Plasma Glucose (FPG)	34	Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)	39
C18	Nutritional and Metabolic	Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)	27	Change From Baseline in Plasma Levels of Hypoxanthine at Day 1, Day 7, Day 14, and at Follow-up	36
C18	Nutritional and Metabolic	Change From Baseline in Fasting Plasma Glucose	22	Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)	26
C18	Nutritional and Metabolic	Change From Baseline in Plasma Levels of Xanthine at Day 1, Day 7, Day 14, and at Follow-up	22	ADDENDUM: Insulin Dose	22
C19	Endocrine System	Change From Baseline in Fasting Plasma Glucose (FPG)	34	7-Point Self-Monitored Blood Glucose (SMBG) Profiles	53
C19	Endocrine System	Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)	27	Change From Baseline in Carbon Monoxide Diffusion Capacity	26
C19	Endocrine System Diseases	Change From Baseline in Fasting Plasma Glucose	22	ADDENDUM: Insulin Dose	22
C19	Endocrine System Diseases	Percent Change From Baseline in ANGPTL3, TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, and Lp(a) at Primary Analysis Time Point	20	Change From Baseline in Fasting Plasma Glucose	21
C19	Endocrine System Diseases	Change From Baseline in Forced Expiratory Volume in One Second (FEV1)	19	INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions	20
C20	Immune System Diseases	Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI	34	Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI	30
C20	Immune System Diseases	Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment	28	Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine	26
C20	Immune System Diseases	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52	27	Change From Baseline in C-Reactive Protein (CRP) at Weeks 1, 2, 4, 8, 12 and 16	18
C20	Immune System	Change From Baseline in C-reactive Protein (CRP) at Weeks 2, 4, 8, 12, 16,	24	7-Point Self-Monitored Blood Glucose (SMBG) Profiles	18
C20	Immune System Diseases	20, 24, 32, 40, 48, and 52 Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and	22	Change From Baseline in Flow Cytometry: 6 Colour TB Natural Killer (NK) Panel- CD16+CD56+, CD19, CD3, CD3+CD4+	16
C23	Pathological Conditions, Signs and Symptoms	Cumulative Percentage of Participants With Treatment Failure	72	Cumulative Percentage of Participants With Treatment Failure	46
C23	Pathological Conditions, Signs and Symptoms	Pain Intensity Difference (PID)	47	Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)	39
C23	Pathological Conditions, Signs and Symptoms	Time-weighted Sum of Pain Intensity Difference (SPID)	18	Pain Intensity Difference (PID)	20
C23	Pathological Conditions, Signs and Symptoms	Percentage of Participants With Treatment Failure	15	Non-opioid Rescue Medication - Ibuprofen	16
C23	Pathological Conditions, Signs and Symptoms	Time to Treatment Failure	12	Non-opioid Rescue Medication - Paracetamol	15
C24	Occupational Diseases	Total Sleep Time Measured by Actigraphy (Nights 6-7)	1	Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7)	3
C24	Occupational Diseases	Sleep Efficiency Measured by Actigraphy (Nights 6-7)	1	Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 13-14)	3
C24	Occupational	Sleep Latency Measured by Actigraphy (Nights 6-7)	1	Total Sleep Time Over a 2-night Average Measured by Polycompography (Nights 6-7)	3
C24	Occupational	Sleep Time Measured by Actigraphy (Nights 6-7)	1	Total Sleep Time Over a 2-night Average Measured by	3
C24	Diseases Occupational	Sleep Time Measured by Actigraphy (Nights 13-14)	1	Polysomnography (Nights 13-14) Sleep Efficiency Over a 2-night Average Measured by	3
C25	Diseases Chemically-	Percent Medication Adherence at 3-month Follow-up Assessment	1	Polysomnography (0-3 Hours) (Nights 6-7) Percentage of Days Used Drugs or Alcohol	2
C25	Induced Disorders Chemically-	Clinician-assessed Depression Rating at 3 Month Follow-up Assessment	1	Length of Hospital Stav	2
C25	Induced Disorders	CD4+ Lymphocyto Count at 12 month Follow un Accorsmont	1	According to a Protection of Protection Mini Lozonger With	-
025	Induced Disorders	CO++ Lympholyte Count at 12-month Follow-up Assessment.	1	Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t (AUC [0-t])	2
C25	Chemically- Induced Disorders	Change in Serum 3a-androstanediol Glucuronide	1	Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve Calculated From Time Zero to Infinity (AIIC [(O-infl)]	2
C25	Chemically-	Time to First Rescue-free Laxation (Following the First Dose of Study	1	Percent Abstinent From Tobacco at Week 32 (7 Day Point Prevalence)	1
C26	Wounds and	Sum of Pain Intensity Difference at Rest and on Weight Bearing Over 6	3	Sum of Pain Intensity Difference at Rest and on Weight Bearing	9
C26	Injuries Wounds and	Hours on Day 1 and Over 2 Hours on Day 3 Number of Patients With Cutaneous Bacterial Load After Surgery	1	Over 6 Hours on Day 1 and Over 2 Hours on Day 3 Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3	3
C26	Injuries Wounds and	Degree of Filling of the Lesion by Repair Tissue at 12 Months Through MRI.	1	Days (SPID WB0-3) Sum of Ankle Pain Intensity Difference on Weight Bearing Over 24	3
C26	Injuries Wounds and	The Difference in Total Bacterial Counts Measured in Colony Forming Units	1	Hours After Dose 1 (SPID WB24) Sum of Pain Intensity Difference at Rest Over 24 Hours on Day 1	2
C26	Injuries Wounds and	(CFU) as Determined by Quantitative PCR Analysis.	1	(SPID R24)	1
520	Injuries	Wounds	-	on the Inside of the Turn)	1
F03 F03	Mental Disorders Mental Disorders	Secondary Emcacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) CSF IL-6, sTREM2, HMGB1, Albumin, IgG	12	Vital Signs: Systolic and Diastolic Blood Pressure Levels Mean Change From Baseline (CFB) at Day 21 in Neurocognitive Function as Determined by Central Nervous System Vital Signs (CNS-VS) Test Battery	9
F03	Mental Disorders	Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)	4	Mean Change From Baseline (CFB) at Day 84 in Neurocognitive Function as Determined by Central Nervous System Vital Signs (CNS-VS) Test Battery	9
F03	Mental Disorders	Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters	4	Incidence of Non-delirium Complications After Surgery	8
F03	Mental Disorders	Target Engagement Assays: Change From Baseline in Filamin A (FLNA) Linkages to alpha7 Nicotinic Acetylcholine Receptor (alpha7nAChR) and Toll-like Receptor 4 (TLR4) in Subject Lymphocytes	4	Median Baseline and Change From Baseline in Body Mass Index (BMI) During Phase 3	6